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Abstract
Background: We assessed the prevalence of risk factors for cardiovascular disease (CVD) in a
middle-income country in rapid epidemiological transition and estimated direct costs for treating
all individuals at increased cardiovascular risk, i.e. following the so-called "high risk strategy".
Methods: Survey of risk factors using an age- and sex-stratified random sample of the population
of Seychelles aged 25–64 in 2004. Assessment of CVD risk and treatment modalities were in line
with international guidelines. Costs are expressed as US$ per capita per year.
Results: 1255 persons took part in the survey (participation rate of 80.2%). Prevalence of main
risk factors was: 39.6% for high blood pressure (≥140/90 mmHg or treatment) of which 59% were
under treatment; 24.2% for high cholesterol (≥6.2 mmol/l); 20.8% for low HDL-cholesterol (<1.0
mmol/l); 9.3% for diabetes (fasting glucose ≥7.0 mmol/l); 17.5% for smoking; 25.1% for obesity
(body mass index ≥30 kg/m2) and 22.1% for the metabolic syndrome. Overall, 43% had HBP, high
cholesterol or diabetes and substantially increased CVD risk. The cost for medications needed to
treat all high-risk individuals amounted to US $45.6, i.e. $11.2 for high blood pressure, $3.8 for
diabetes, and $30.6 for dyslipidemia (using generic drugs except for hypercholesterolemia). Cost
for minimal follow-up medical care and laboratory tests amounted to $22.6.
Conclusion: High prevalence of major risk factors was found in a rapidly developing country and
costs for treatment needed to reduce risk factors in all high-risk individuals exceeded resources
generally available in low or middle income countries. Our findings emphasize the need for
affordable cost-effective treatment strategies and the critical importance of population strategies
aimed at reducing risk factors in the entire population.
Background
Cardiovascular diseases (CVD) have become a leading
cause of mortality and morbidity in developing countries
and rates are expected to rise further over the next few dec-
ades [1-4]. In particular, it has been estimated that high
blood pressure (HBP) accounts for as much as 5.0% of the
total mortality in middle-income countries, tobacco for
4.0%, high cholesterol for 2.1% and obesity for 2.7% [5].
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The increasing burden of CVD has important economic
implications. CVD occurs typically at a younger age in
developing than developed countries with important con-
sequences such as loss of revenue at household level and
loss of productivity at macroeconomic level. From a
health system perspective, huge resources are needed for
providing health care to large numbers of chronic patients
for decades and for sustaining increasingly sophisticated
equipment and more skilled and harder-to-replace work-
force [6-8].
There are two approaches to reduce the burden of CVD
[7]. The population strategy, that includes community-
based programs and health promoting policies, recog-
nizes that several modifiable CVD risk factors are widely
distributed in the population and that small change in
CVD risk among large numbers of people can reduce
largely the incidence of CVD in the population. The alter-
native is to target "high risk" people, i.e. risk factors are
screened in the population and persons with high risk of
CVD are treated. These alternative strategies, "population"
and "high risk", can of course be considered as comple-
mentary.
In this study, we examined the prevalence of risk factors in
the adult population of Seychelles, a country that has
experienced rapid socio economic development over the
past few decades. We then estimated the direct cost of
treatment of all high-risk individuals (i.e. medication and
simple related medical follow-up). The interest of this
case study is enhanced by the fact that Seychelles recently
switched its medication procurement system toward a
broader use of generic drugs and direct cost estimates can
be estimated for both systems.
Methods
The Republic of Seychelles is a group of islands in the
Indian Ocean approximately 1800 km east to Kenya. A
large majority of the population is of African descent.
Health care (including medication) is available at no
direct cost at the point of delivery to all residents through
a National Health System while a few private doctors also
provide services on a fee-paying basis. The gross domestic
product (GDP) per capita increased from US$600 in 1976
to US$8492 in 2003. Annual government expenditure on
health was US$307 per capita per year [10]. All deaths are
registered in Seychelles and Vital Statistics indicate a life
expectancy of 69 years in men and 76 years in women.
AIDS and CVD account for respectively approximately 1%
and 38% of total mortality [11].
A population-based survey of cardiovascular risk factors
was conducted in 2004 under the auspices of the Ministry
of Health of the Republic of Seychelles (Seychelles Heart
Study III). The sampling frame consisted of a sex- and age-
stratified random sample of the entire population aged
25–64. Eligible participants were selected from computer-
ized data of a national population census in 2002 thereaf-
ter updated by civil status authorities. Eligible persons
were invited to attend study centers on the 3 main islands
through a personal letter and requested to be fasting since
midnight when they attend. The survey was approved by
the Ministry of Health after technical and ethical reviews.
Participants were free to participate and gave written
informed consent.
Smoking was defined as reported smoking at least one cig-
arette per day. Blood pressure was defined as the average
of the last two of three measurements with a mercury
sphygmomanometer taken at intervals longer than 2 min-
utes after the participants had been seating for at least 30
minutes. BP categories are defined along current guide-
lines [12-15]. Weight was measured with electronic med-
ical scales (Seca, Germany) and height measured with
fixed stadiometers (Seca). Body mass index (BMI) was cal-
culated as weight divided by height squared (kg/m2) and
obesity defined as BMI ≥30 kg/m2.
Blood was taken between 7:00 and 10:00 in the morning
and on another day for the few participants who reported
to be non-fasting. Serum was obtained within 2 hours of
blood collection and immediately frozen to -20°C. Blood
lipids were measured at the Canton Laboratory for Bio-
chemistry and Haematology, St Gallen, Switzerland.
Blood cholesterol was measured by an enzymatic colori-
metric test using cholesterol esterase and cholesterol oxi-
dase (CHOD-PAP, Roche) on a Hitachi 917
instrument(Roche). Triglycerides were measured with an
enzymatic colorimetric test GPO-PAP, Roche) on a
Hitachi 917 instrument (Roche). HDL-cholesterol was
measured with a homogeneous enzymatic colorimetric
test (HDL-C plus 2nd generation, Roche) using Dextran-
sulfate and PEG-modified enzyme on a Hitachi 917
instrument. Blood lipids categories are in line with current
guidelines [16].
Fasting plasma glucose was measured with a point-of-care
analyzer (Cholestec LDX, Hayward, USA) in all partici-
pants. If glucose was ≥5.6 mmol/l, an additional capillary
measurement was performed within 10 minutes (Ascen-
cia Elite glucometer, Bayer). The average of the two read-
ings was considered. Diabetes was defined as fasting
blood glucose ≥7.0 mmol/l [17]. The metabolic syndrome
was defined along the American guidelines [16], which
requires 3 or more of the following: increased waist (>102
cm in men and >88 in women), increased triglycerides
(≥1.7 mmol/l), low HDL-cholesterol (<1.03 mmol/l in
men and 1.29 in women), elevated BP (≥130/85 mmHg),
and increased fasting blood glucose (≥6.1 mmol/l).B
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Table 1: Prevalence (and 95% confidence intervals) of risk factors in the adult population of Seychelles
Men Women Population aged 25–64*
25–34 35–44 45–54 55–64 25–34 35–44 45–54 55–64 Men Women Total
Smoking 30.2 32.1 31.2 29.3 4.0 4.0 3.9 3.3 30.8 3.9 17.4
22.7–38.8 24.7–40.5 24.4–38.9 22.6–37.1 1.8–8.7 1.9–8.1 1.9–7.9 1.5–7.2 27.0–34.9 2.6–5.7 15.3–19.7
Overweight (BMI ≥25 kg/m2) 41.3 55.2 63.3 50.7 55.0 67.6 76.2 83.4 52.0 68.3 60.1
33.0–50.1 46.7–63.5 55.5–70.5 42.7–58.6 46.9–62.9 60.3–74.1 69.5–81.9 77.3–88.2 47.7–56.2 64.5–71.8 57.2–62.9
Obesity (BMI ≥30 kg/m2) 9.5 14.9 22.8 14.7 22.8 37.5 39.8 48.1 15.0 35.2 25.1
5.5–16.1 9.8–22.1 16.9–30.0 9.8–21.3 16.8–30.3 30.6–44.9 32.9–47.1 40.9–55.4 12.3–18.3 31.6–38.8 22.8–27.5
HBP grade ≥1 (≥140/90 mmHg) 20.6 33.6 49.4 64.7 6.0 19.9 39.2 48.6 38.4 24.8 31.6
14.4-28-6 26.1–42.0 41.6–57.2 56.7-71-9 3.2–11.2 14.6–26,5 32.3–46.5 41.4–55.9 34.6–42.3 22.0–27.9 29.1–34.2
HBP grade ≥2 (≥160/100 mmHg) 5.6 7.5 22.2 24.7 1.3 5.1 16.0 18.8 13.2 8.8 11.0
2.7–11.2 4.1–13.4 16.3–29.3 18.4–32.2 0.3–5.2 2.7–8.6 11.3–22.1 13.7–25.2 10.8–16.1 7.0–10.8 9.4–12.8
Current treatment for HBP 5.6 14.9 32.9 46.0 6.0 18.2 37.6 58.6 21.4 25.6 23.5
2.7–11.2 9.8–22.1 26.5–40.7 28.2–54.1 3.2–11.2 13.1–24.6 30.8–44.9 51.2–65.5 18.5–24.6 22.8–28.6 21.4–25.7
HBP grade ≥1 or treatment 23.0 38.8 56.3 72.7 10.1 30.1 51.9 70.2 43.6 35.5 39.6
15.5–31.2 30.9–47.4 48.5–63.9 65.0–79.2 6.1–16.1 23.8–37.3 44.6–59.2 63.1–76.4 40.0–47.6 32.4–38.8 36.9–42.3
TC borderline or high (≥5.2 mmol/l) 41.3 55.2 57.6 53.3 36.2 48.3 60.2 69.6 51.1 50.8 51.0
33.0–50.0 46.7–63.5 49.7–65.1 45.3–61.2 28.9–44.3 41.0–55.7 52.9–67.1 62.5–75.9 46.8–55.3 47.0–54.6 48.1–53.8
TC high (≥6.2 mmol/)l 17.5 31.3 29.8 26.7 16.1 14.8 32.0 53.6 25.8 25.7 24.2
11.7–25.2 24.0–39.7 23.1–37.4 20.2–34.4 11.0–23.0 10.2–20.8 25.6–39.2 46.3–60.7 22.3–29.7 22.7–28.9 23.4–28.3
HDL-C low (<1.0 mmol/l) 19.8 31.3 28.5 20.0 14.8 12.5 20.4 21 25.2 16.5 20.8
13.7–27.8 24.0–39.7 22.0–36.1 14.3–27.2 10.0–21.5 8.4–18.3 15.2–27.0 15.7–27.6 21.6–29.1 13.8–19.5 18.6-23-3
Diabetes (FBG≥7.0 mmol/l) 0.8 9.7 12.7 22.0 2.0 4.6 11.6 26.5 9.6 9.0 9.3
0.1–5.5 5.7–16.0 8.3–18.9 16.1–29.3 0.6–6.1 2.3–8.9 7.7–17.2 20.6–33.4 7.6–12.1 7.3–11.2 7.9–10.9
Metabolic syndrome 4.9 19.4 29.1 28.5 9.4 21.6 36.1 48.0 18.7 25.5 22.1
2.2–10.5 13.3–27.0 22.5–36.7 21.7–36.4 5.6–15.3 16.1–28.3 29.4–43.4 40.8–55.4 15.7–21.9 22.5–28.7 20.0–24.3
HBP: high blood pressure; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; FBG: fasting blood glucose.
* Overall estimates are adjusted to the distribution of the new World Health Organization standard population (19)BMC Public Health 2006, 6:9 http://www.biomedcentral.com/1471-2458/6/9
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For HBP, medical treatment was assumed for persons at
'medium' or 'high' CVD risk, as defined in WHO guideline
[12]. In assessing CVD risk, we considered the following
associated risk factors: age ≥55 for men (≥65 for women),
obesity, high blood cholesterol (≥6.2 mmol/l), and low
HDL-cholesterol. Low HDL-cholesterol was defined as <1
mmol/l for both men and women [16].
When assessing CVD risk in diabetic patients, we consid-
ered HBP (≥140/90 mmHg or antihypertensive treat-
ment) and the risk factors mentioned in the paragraph
above [12]. We considered total cholesterol levels alone
(i.e. without considering HDL-cholesterol) for the pur-
pose of simplicity and assuming that the number of cases
with elevated total cholesterol and high HDL-cholesterol
(possibly not requiring treatment) would be similar to the
number of cases with moderately elevated cholesterol and
low HDL-cholesterol (possibly requiring treatment).
Consistent with efficacy and cost considerations [12-
14,18], treatment for HBP was assumed to include a diu-
retic as first choice for mono-therapy in 80% of cases, a
diuretic in all combinations, and an approach favoring
low-dose combinations. The different combinations (bi,
tri or tetra-therapy) assumed to be used for treatment of
HBP across different CVD risk categories was estimated by
consensus with local physicians. For diabetes, 20 units
insulin were assumed to be used in 10% of cases of per-
sons with glucose ≥10 mmol/l, in addition to oral anti-
diabetic drugs, assuming that most persons with diabetes
had type II diabetes. For the few cases with type I diabetes,
who do not need oral treatment, the cost for oral diabetic
drugs accounted for in our model was assumed to com-
pensate for the larger cost of higher insulin dose needed
in type I diabetes.
Costs of medications are provided for both 2004 and
2005 because, in 2005, the Ministry of Health adopted a
new procurement system in favor of generic medications.
Prices of blood tests assumed to be performed for medical
follow-up were provided by the laboratory of the main
hospital of Seychelles. We assumed the price of a medical
visit in the public service as the average between the min-
imal cost charged by private doctors (SCR 75) and the
amount of SCR10 corresponding to 15 minutes of a typi-
cal salary of general practitioners in the public service.
This compromise recognizes an additional cost for serv-
ices contributed by nurses, clerks and administrative staff
in addition to medical visit time in the public service. The
number of 4 consultations per year was assumed, consist-
ent with standard practice for chronic patients who need
renewal of prescriptions every three months in the public
service.
Biochemical investigations assumed in our estimates
included one series of basic tests per year for all cases with
either HBP, diabetes or dyslipidemia (i.e. costs for screen-
ing in the population are not included). In addition, dia-
betic patients were assumed to have blood glucose
measured quarterly and HbA1c measured biannually. The
tests are available in public health centers in Seychelles.
The prevalence of risk factors has been tabulated by age
and sex and overall estimates are weighted to the distribu-
tion of the new World Health Organization standard pop-
ulation [19]. Costs in the entire population are expressed
in Seychelles rupees (SCR) per year. Costs per capita of the
entire population per year (in US$; 1$ ~5 SCR) provide
cost estimates that are independent of the size of the pop-
ulation. When estimating costs of the treatment strategy in
the entire population, we assumed same risk factor preva-
lence and medication patterns in persons aged ≥65 years
as in the population aged 25–64; a zero prevalence of risk
factors in persons aged less than 25; and a same preva-
lence of risk factors in 2004 and 2005. Analyses were per-
formed with Stata 8.2.
Results
From the initial sex and age stratified sample of 1632 men
and women aged 25–64, 69 were dead, had emigrated, or
could not be traced. From the 1563 eligible persons, 1255
participated in the survey (80.2%). Participation was 67%
among men aged 25–34, above 70% for men in other 10-
year age categories and above 80% for women in all 10-
year categories. Participation did not differ across study
centers.
Table 1 shows the prevalence of main risk factors and dia-
betes by age and sex (adjusted to the WHO standard pop-
ulation). The prevalence of HBP increased sharply with
age and was higher in men than women. The prevalence
of BP ≥140/90 mmHg and BP ≥160/100 mmHg was
31.6% and 11.0%, respectively. Among persons with BP
≥140/90 mmHg, 49.1% were currently taking antihyper-
tension treatment. Around half of men and women aged
25–64 had serum cholesterol that exceeded optimal levels
(≥5.2 mmol/l). A quarter of both men and women had
high cholesterol levels (≥6.2 mmol/l). Approximately one
fifth of men or women had low serum HDL-cholesterol
(<1 mmol/l). The prevalence of HDL-cholesterol <1.3
mmol/l was 48.9% in women. The prevalence of diabetes
increased sharply with age with an overall prevalence of
9.3%. As many as 68.3% of women and 52.0% of men
had BMI ≥25 kg/m2 and 35% of women and 15% of men
were obese (≥30 kg/m2). Smoking was reported by 30.8%
of men and 3.9% of women. The prevalence of the meta-
bolic syndrome (age 25–64) was high at 25.5% in women
and 18.7% in men.BMC Public Health 2006, 6:9 http://www.biomedcentral.com/1471-2458/6/9
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The prices of medications available in public health serv-
ices in Seychelles were considerably lower in 2005 than in
2004 (Table 2), consistent with lower cost of generic drugs
used in 2005 vs. 2004 (except for statins).
Table 3 shows the distribution of CVD risk categories
across categories of HBP, increased levels of blood choles-
terol and diabetes. The table also shows treatment
assumed to be used for HBP, high cholesterol and diabe-
tes. Noticeably, the prevalence of persons with HBP, dia-
betes or hypercholesterolemia (42.7%) was only slightly
larger than the prevalence of HBP alone, indicating that
these conditions tended to cluster in same individuals.
The cost per capita per year for treating all affected persons
at "medium" or "high" CVD risk, in 2004 and 2005
respectively, amounted to respectively $30.4 and $11.2
for hypertension; $21.5 and $3.8 for diabetes; and $32.7
and $30.6 for hypercholesterolemia. The total cost of
medications needed to treat all three conditions in the
entire population would be $45.6 per capita per year in
2004 and $84.6 in 2005. This emphasizes the large cost
reduction that resulted from switching to generic drugs in
2005.
Table 4 shows the cost for selected services for medical
care of HBP, diabetes and dyslipidemia. The cost of med-
ical visits could amount to $8.2 while laboratory exams
could cost an additional $14.4 (a total of $22.6). Since
HBP is much more prevalent than diabetes or hypercho-
lesterolemia and because the considered risk factors tend
to cluster (71% of persons with diabetes and 50% of per-
sons with hypercholesterolemia also had HBP), the cost
of these selected services was largely driven by treatment
of HBP.
Discussion
This paper examines the prevalence of major risk factors
in a developing country and the costs of one specific strat-
egy to prevent CVD, i.e. the identification and drug treat-
ment of persons at high risk. The analysis is restricted to
direct costs of the intervention (medication and medical
follow-up), an immediate and practical issue for health
care providers and patients. The case of Seychelles is inter-
esting because it is a middle-income developing country;
the prevalence of risk factors is based on recent popula-
tion data; at least one medication from all major medica-
tion classes are available in the public sector; and the
national health system allows for providing treatment to
all high-risk individuals.
The survey showed high levels of the major CVD risk fac-
tors in a rapidly developing middle-income country. Prev-
alence in 2004 can be compared with data of a similarly
designed population survey in 1989 (20,21). Adjusted to
the WHO standard population, the overall prevalence of
HBP (BP ≥140/90) was lower in 2004 than 1989 (31.6%
vs. 38.6%, population aged 25–64), probably reflecting
the larger proportion of persons with HBP under treat-
ment in 2004 than in 1989 (59.3% vs. 21.9%). The higher
prevalence of overweight in 2004 than in 1989 can relate
to rapid socio-economic development [22], with large
increase in motorised transport and service-oriented econ-
omy. This may account for the higher prevalence of diabe-
tes and, to some extent, hypercholesterolemia (both
higher in 2004 than in 1989). The prevalence of smoking
was substantially lower in 2004 than in 1989, consistent
with sustained government tobacco control interventions,
including high taxes on tobacco products, advertising
ban, education programs, ratification of the Framework
Convention of Tobacco Control in 2003 and comprehen-
sive legislation enacted in 2005.
We used conservative assumptions in our estimation
model and costs for a treatment strategy provided in our
study are likely to correspond to minimal figures. Our
assessment of CVD risk did not include several indicators
of CVD that are difficult to quantify, e.g. risk factors such
as sedentary habits or family history of CVD and other
markers of risk (target-organ damage, associated clinical
conditions except for diabetes, or established CVD). Our
cut-off values for age (≥55 years for men), total cholesterol
(≥6.2 mmol/l) or HDL cholesterol in women (<1 mmol/
l) are less stringent than in other guidelines. Measurement
of blood pressure on one single visit tends to overestimate
the prevalence of hypertension [23] but this may be par-
tially compensated by the use of blood pressure values
unadjusted for antihypertensive treatment (i.e. another
source of underestimation of an individual's CVD risk).
Overall, it is likely that we assessed CVD risk conserva-
tively so that medical treatment would be justified for
most patients labeled in our study as 'medium' or 'high
risk'. We also used conservative criteria for the nature and
frequency of biochemical analyses assumed for medical
follow-up of high risk patients in our estimation. In par-
ticular, we did not include urine analysis, electrocardio-
gram, fundoscopy and others tests usually found useful in
the circumstances. Also, we did not include interventions,
such as aspirin, intended mainly for secondary prevention
of CVD.
The cost of medications accounted for approximately two
thirds of the total cost of the treatment strategy. It follows
that a decreased price of medications will reduce the total
direct cost of the treatment strategy. We show that by
using generic rather than proprietary medications, the cost
of medications alone could be substantially reduced: from
$30 to $11 per capita per year for hypertension and from
$22 to $4 for diabetes. The cost of medication for dyslipi-
demia could potentially be similarly reduced if generic
medications were used. Although new statins are moreBMC Public Health 2006, 6:9 http://www.biomedcentral.com/1471-2458/6/9
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powerful than older ones, the majority of subjects with
elevated blood cholesterol would get to target even with
the older agents while only a minority of patients at very
high risk would need the latter to reach recommended
very low LDL targets.
The cost of basic medical follow-up for high-risk patients,
both investigations and medical visits ($23 per capita per
year) is less compressible and indeed likely to increase
under the pressure of increasing patients' expectations and
other factors such as rising health care personnel costs.
This emphasizes the need for guidelines to ensure that uti-
lization of scarce resources is not unduly influenced by
local or global commercial interests but used in a cost-
effective way [24].
At a minimum of $68 per capita, the estimated direct costs
for medications and basic medical follow-up for all high-
risk individuals is a major burden on the health budget.
Even at half of that cost to account for half of the preva-
lence of risk factors found in this study -a situation more
typical of populations at earlier stages of the epidemiolog-
ical transition-, treating risk factors in the population
would remain out of reach for many developing coun-
tries. Indeed, many developing countries rely on govern-
ment health budget lower than $50 per capita per year -vs.
$3000–5000 in western countries- [10] and a large pro-
portion is absorbed to control the persisting large burden
of infectious diseases. There has been much debate as to
whether medical treatment for chronic conditions can be
afforded in low resource settings, in view of high cost of
life-long medication and, indeed, high cost per year of life
saved compared to interventions for other conditions
[25]. It has been argued that scarce resources could be bet-
ter invested in more cost-effective or urgent medical or
other interventions [26,27]. It would however be inequi-
table to deny treatment of demonstrated efficacy to some
or all individuals who would benefit of it [28].
We considered costs in the public sector, which provides
universal coverage for health care in Seychelles. We have
not investigated or compared costs and prices in the pri-
vate sector, which remains relatively small. Currently, the
public services are financed from taxation revenue, an
approach aimed at providing more equitable provision of
care to the population. Increasing pressure for the intro-
duction of user fees is likely to impact negatively on those
who are most vulnerable and least able or willing to pay.
Furthermore, direct cost for medical treatment of elevated
risk factors is of course only one component in the spec-
trum of medical care required and, more generally, in
cost-benefit analysis. Costs can be averted as well, such as
hospitalization and loss of productivity, therefore poten-
tially reducing the overall cost of a high-risk strategy. In
Seychelles, where some special care is available -e.g.
hemodialysis but not revascularization-, the costs averted
can be significant. However, these costs may not be imme-
diate in many low and middle income countries, since
hospitalization and surgery may not be available and low
formal employment makes evaluation of the cost of lost
productivity uncertain. Clearly, comprehensive cost-bene-
Table 2: Medications considered in estimation of costs for treatment for high blood pressure, hypercholesterolemia, and diabetes
Cost per day (SCR)
Dose per day 2004 2005
Daily dose and cost of medications
Metformin 1.5 g 4.83 0.48
Glibenclamide 10 mg 1.22 0.18
Insulin (2004:standard; 2005: pen) 20 units 3.40 7.72
Rosuvastatin (2004: Atorvastatin) 10 mg 7.81 7.31
Bendrofluazide (D) 2.5 mg 0.04 0.05
Atenolol (BB) 50 mg 0.67 0.21
Amlodipin (CCB) 5 mg 2.74 0.51
Lisinopril (ACEI) 20 mg 4.00 1.89
Valsartan (ARB) 80 mg 8.50 5.82
Combinations for treatment of hypertension (mono-, bi-, tri- or quadri-therapy)
D in 80% of cases or any of (BB, CCB or ACEI/ARB) in 20% of cases Mono 0.52 0.21
D + any of (BB or CCB or ACEI/ARB) Bi 2.51 0.92
D + BB + any of (CCB +ACEI/ARB) Tri 4.08 1.46
D + BB +CCB + (ACEI/ARB) Quadri 7.45 2.66
Average cost of Lisinopril in 90% cases or Valsartan in 10% of cases (ACEI/ARB) 4.45 2.28
Average cost of either BB or CCB or ACEI/ARB 2.47 0.87
Average cost of either CCB or ACEI/ARB 3.37 1.20
US$1 ~ SCR5B
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Table 3: Distribution of cardiovascular risk categories and estimated costs associated with treatment of hypertension, dyslipidemia and diabetes mellitus
Cost
2004 2005
Condition/criterion Associated 
conditions
Risk* Medication Prevalence in 
population aged 
25–64 (%)
Cost per day 
per treated 
patient 
(SCR)
Annual cost for 
all cases aged 
≥25 yrs (SCR 
million)
Per capita cost 
for total 
population per 
year (US$)
Cost per day 
per treated 
patient 
(SCR)
Annual cost for 
all cases aged 
≥25 yrs (SCR 
million)
Per capita cost 
for total 
population per 
year (US$)
Diabetes (DM)
FBG ≥10 mmol/l High Metformin 1.5 g/d & 
Glibenclamide 10 mg/
d
4.9 6.05 4.95 12.4 0.66 0.54 1.3
Addition of insulin 20 
U (in 10% of cases)
3.40 0.28 0.7 7.72 0.63 1.6
FBG 7–9 mmol/l High Metformin 1.5 g/d 3.6 4.83 2.92 7.3 0.48 0.29 0.7
FBG <7 mmol/l Treatment for 
DM
High Metformin 1 g/d 0.9 3.19 0.45 1.1 0.32 0.05 0.1
Total diabetes 9.3 8.60 21.5 1.51 3.8
Hypertension
≥180/110 mmHg - High 2 drugs (20%), 3 
drugs (70%), 4 drugs 
(10%)
3.1 4.10 2.11 5.3 1.47 0.76 1.9
160–179/100–109 ≥3 MRF or DM High 2 drugs (60%), 3 
drugs (30%), 4 drugs 
(10%)
2.3 3.47 1.33 3.3 1.26 0.48 1.2
160–179/100–109 0–2 MRF, not 
DM
Medium 1 drug (10%), 2 drugs 
(60%), 3 drugs (30%)
5.6 2.78 2.63 6.6 1.01 0.96 2.4
140–159/90–99 ≥3 MRF or DM High 1 drug (20%), 2 drugs 
(70%), 3 drugs (10%)
5.6 2.27 2.14 5.4 0.83 0.79 2.0
140–159/90–99 1–2 MRF, not 
DM
Medium 1 drug (60%), 2 drugs 
(40%)
12.1 1.32 2.67 6.7 0.50 1.01 2.5
140–159/90–99 0 MRF Low - 4.3 0 0
<140/90 Treatment and 
≥1 MRF
≥Medium 1 drug (70%), 2 drugs 
(30%)
6.9 1.12 1.28 3.2 0.43 0.49 1.2
Total hypertension 39.9 12.16 30.4 4.48 11.2
High cholesterol
≥8 mmol/l High Rosuvastatin 10 mg/d 
(80%), 20 mg (20%)
3.1 9.37 4.80 12.0 8.77 4.49 11.2
7–7.9 mmol/l ≥2 MRF or DM High Rosuvastatin 10 mg/d 3.5 7.81 4.56 11.4 7.31 4.27 10.7
6–6.9 mmol/l ≥3 MRF or DM High Rosuvastatin 10 mg/d 2.8 7.81 3.71 9.3 7.31 3.47 8.7
Total dyslipidemia 9.4 13.07 32.7 12.24 30.6
Any condition 42.7 33.8 84.6 18.22 45.6
*CVD risk assessed based on following risk factors: age ≥55 for men; smoking; total cholesterol ≥6.2 mmol/l (240 mg/dl); HDL-cholesterol <1.0 mmol/l (40 mg/dl), BP ≥140/90 mmHg or 
treatment, obesity (body mass index ≥30 kg/m2); SCR: Seychelles rupees.BMC Public Health 2006, 6:9 http://www.biomedcentral.com/1471-2458/6/9
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fit analysis is a greater challenge in developing countries
in the absence of documented evidence on the magnitude
of such factors. While adopting a simplified approach, the
analysis presented in this paper does provide approximate
direct costs that must actually be borne in providing high-
risk individuals with medication and care.
The high cost of a treatment strategy stresses the need to
identify alternative and more affordable strategies.
Emphasis has been put on the need to inform individual
clinical treatment based on the probable size of absolute
treatment benefits, i.e. based on an individual's CVD total
risk, not just risk factor levels [29,30]. A major issue is to
choose CVD risk thresholds that can maximize events pre-
vented without increasing the total numbers treated in a
defined population. However, assessing CVD risk is chal-
lenging in populations for which cohort data are not
available and calculation of CVD risk along current west-
ern-based risk functions cannot be calibrated. A radically
different strategy, recently proposed, would consist of pro-
viding a low-cost "polypill" combining several medica-
tions (e.g. three antihypertensive drugs, a statin, aspirin)
to all persons aged 55 years and above, given that CVD
risk is predominantly driven by age [31]. This approach
may well be far less expensive than traditional treatment
strategies because of expectedly much lower cost of such a
polypill (use of generic drugs, economy of scale) and the
avoidance of medical follow-up. However, clinical trials
will have first to demonstrate the effectiveness, safety, and
acceptability of such a strategy.
Even if drug prices are reduced, strategies relying on med-
ications may still be unaffordable for many low or middle
income countries. In addition, several factors inherently
limit the impact of treatment strategies at a population
level, e.g. poor compliance to medications for asympto-
matic chronic conditions [32] and limited control of
hypertension or diabetes in many instances, even with
multi-drug combinations. Furthermore, approaches
based on the assessment of lifetime CVD risk imply that
individuals will have accumulated much of their risk (e.g.
developed substantial atherosclerosis) before they
become eligible for treatment [33].
Although a high-risk approach can be an important com-
ponent of a global strategy to reduce CVD [34], evidence
strongly supports the predominant role of primary pre-
vention[35]. Interventions typically include policies
aimed at changing the societal milieu to enable a broad
adoption of healthy lifestyles [36]. In addition, by
decreasing risk factor levels in the population (or main-
taining favorable levels in some developing countries in
early epidemiological transition), primary prevention can
substantially minimize the number of persons at high
CVD risk in need of medical treatment for hypertension,
dyslipidemia or type II diabetes. Ultimately, the interests
of the population at large are served by broad improve-
ments in the quality of life, which includes both a reduc-
tion in morbidity as well as a decrease in fatal events.
Since prevention delivers the best results in terms of qual-
ity of life, that should be sufficient reason to rank it as the
top priority for public health interventions. Economic
Table 4: Estimated costs of medical care for hypertension, diabetes and dyslipidemia
Unit cost 
(SCR)
Number done 
each year (n)
Cost per year 
(SCR)
Prevalence in 
population aged 
25–64 (%)
Cost in population 
per year (SCR 
million)
Cost per capita 
and per year (US$)
Medical consultations 42 4 168 42.7 3.3 8.24
Blood tests for all persons with 
hypertension, diabetes or high 
cholesterol
Glucose 30 1 30 42.7 0.6 1.47
Creatinine 30 1 30 42.7 0.6 1.47
Sodium 30 1 30 42.7 0.6 1.47
Potassium 30 1 30 42.7 0.6 1.47
Total cholesterol 30 1 30 42.7 0.6 1.47
HDL-cholesterol 50 1 50 42.7 1.0 2.45
Triglycerides 30 1 30 42.7 0.6 1.47
Subtotal 42.7 6.2 11.3
Additional blood tests for all 
persons with diabetes
Glucose 30 3 90 9.3 0.4 0.96
HbA1c 100 2 200 9.3 0.9 2.14
Subtotal 1.2 3.1
All blood tests 7.5 14.4
All blood tests and consultations 10.8 22.6
SCR: Seychelles rupeesBMC Public Health 2006, 6:9 http://www.biomedcentral.com/1471-2458/6/9
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considerations alone cannot be the primary criteria that
lead to the choice of the primary prevention strategy vs.
the high risk strategy.
Conclusion
High prevalence of major risks factors was found in a rap-
idly developing country. Cost for treatment needed to
reduce risk factors in all high-risk individuals exceeded
resources generally available in low or middle income
countries. These findings stress the need for affordable,
cost-effective treatment strategies and the critical impor-
tance of public health strategies aimed at reducing risk fac-
tors in the entire population.
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